Amato RJ - Search Results

1

Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors.

Fizazi K, Culine S, Kramar A, Amato RJ, Bouzy J, Chen I, Droz JP, Logothetis CJ. Fizazi K, et al. Among authors: amato rj. J Clin Oncol. 2004 Oct 1;22(19):3868-76. doi: 10.1200/JCO.2004.04.008. Epub 2004 Aug 9. J Clin Oncol. 2004. PMID: 15302906

2

A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial.

Fizazi K, Do KA, Wang X, Finn L, Logothetis CJ, Amato RJ. Fizazi K, et al. Among authors: amato rj. Ann Oncol. 2002 Jan;13(1):125-34. doi: 10.1093/annonc/mdf005. Ann Oncol. 2002. PMID: 11863094 Free article. Clinical Trial.

3

Predictive factors for effective salvage therapy of nonseminomatous germ cell tumors of testis.

Dimopoulos MA, Amato RJ, Logothetis CJ. Dimopoulos MA, et al. Among authors: amato rj. Urology. 1991 Oct;38(4):351-4. doi: 10.1016/0090-4295(91)80151-v. Urology. 1991. PMID: 1661457

4

Germ cell tumors in patients infected by the human immunodeficiency virus.

Fizazi K, Amato RJ, Beuzeboc P, Petit N, Bouhour D, Thiss A, Rebischung C, Chevreau C, Logothetis CJ, Droz JP. Fizazi K, et al. Among authors: amato rj. Cancer. 2001 Sep 15;92(6):1460-7. doi: 10.1002/1097-0142(20010915)92:6<1460::aid-cncr1470>3.0.co;2-i. Cancer. 2001. PMID: 11745223

5

Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.

Fizazi K, Prow DM, Do KA, Wang X, Finn L, Kim J, Daliani D, Papandreou CN, Tu SM, Millikan RE, Pagliaro LC, Logothetis CJ, Amato RJ. Fizazi K, et al. Among authors: amato rj. Br J Cancer. 2002 May 20;86(10):1555-60. doi: 10.1038/sj.bjc.6600272. Br J Cancer. 2002. PMID: 12085204 Free PMC article. Clinical Trial.

6

Chemotherapy immediately after surgery for patients with germ cell tumors.

Sella A, Logothetis CJ, Dexeus FH, Amato R. Sella A, et al. Urology. 1990 Sep;36(3):264-6. doi: 10.1016/0090-4295(90)80270-w. Urology. 1990. PMID: 2168105

7

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.

Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG, Kilbourn RG. Logothetis CJ, et al. Among authors: amato rj. J Clin Oncol. 1990 Jun;8(6):1050-5. doi: 10.1200/JCO.1990.8.6.1050. J Clin Oncol. 1990. PMID: 2189954 Clinical Trial.

8

Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial.

Logothetis CJ, Finn LD, Smith T, Kilbourn RG, Ellerhorst JA, Zukiwski AA, Sella A, Tu SM, Amato RJ. Logothetis CJ, et al. Among authors: amato rj. J Clin Oncol. 1995 Sep;13(9):2272-7. doi: 10.1200/JCO.1995.13.9.2272. J Clin Oncol. 1995. PMID: 7666085 Clinical Trial.

9

Phase II study of coumarin and cimetidine in patients with metastatic renal cell carcinoma.

Dexeus FH, Logothetis CJ, Sella A, Fitz K, Amato R, Reuben JM, Dozier N. Dexeus FH, et al. J Clin Oncol. 1990 Feb;8(2):325-9. doi: 10.1200/JCO.1990.8.2.325. J Clin Oncol. 1990. PMID: 2137163

10

Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer.

Sella A, Kilbourn R, Amato R, Bui C, Zukiwski AA, Ellerhorst J, Logothetis CJ. Sella A, et al. J Clin Oncol. 1994 Apr;12(4):683-8. doi: 10.1200/JCO.1994.12.4.683. J Clin Oncol. 1994. PMID: 7512126 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

271 results

Search Page

Filters